SAN FRANCISCO, Dec. 14 /PRNewswire/ -- BabyCenter.com was named the best Web site in the Health category at the fourth annual Global Information Infrastructure (GII) Awards announced here today. The awards were presented at a gala ceremony at the Westin St. Francis Hotel in conjunction with the Nextravaganza conference
TORONTO--(BUSINESS WIRE)--Dec. 10, 1999--HIV-VAC, Inc., (OTC/BB: HIVC) today announced that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, the developer of HIV-VAC s AIDS vaccine, said, that with a record 2.6 million people dying from AIDS in 1999, and another 5.6 million infected, the only answer to halting this
FOSTER CITY, Calif.--(BW HealthWire)--Dec. 3, 1999-- Gilead Sciences (NASDAQ: GILD) announced today the termination of its U.S. HIV development program for the investigational agent adefovir dipivoxil 60 mg. This decision follows a U.S. Food and Drug Administration ( FDA ) Advisory Committee meeting on N
Who: Edward Hooper, author of THE RIVER: A Journey To The Source of AIDS, published by Little, Brown and Company When: Tuesday, December 7, 1999, 10:00 am Where: 75 Rockefeller Plaza/ Time Warner Bldg. 4th Floor, Room 433 What: Press Conference with Edward Hooper For the last ten years, distinguished science journalist
DURHAM, N.C.--(BW HealthWire)--Nov. 30, 1999-- Pediatric AIDS Clinical Trials Group Initiates First Study of Anti-HIV Fusion Inhibitor, Offering Potential New Treatment Option Trimeris Inc. (NASDAQ: TRMS) and Hoffmann-La Roche Inc. announced today that dosing has started in the first clinical study in HIV-positive chil
SEATTLE--(BUSINESS WIRE)--Nov. 23, 1999--What do some of today s hottest artists like Sarah McLachlan, Seattle s own Heart, and Shawn Colvin have in common with Melky Sedeck, Aztec Camera, and The Go-Go s? These chart topping acts, along with many others, have come together to whet your musical palate with classic cove
SAN FRANCISCO--(BW HealthWire)--Nov. 23, 1999--This year s theme for World AIDS Day, observed December 1, will be Ending the Silence -- a mission embraced wholeheartedly by Gay.com, The Gay Network (www.gay.com) and its special guest experts that day. On Wednesday, December 1, Gay.com will present a distinctive hour-lo
SAN FRANCISCO--(BW HealthWire)--Nov. 22, 1999--Metreon, along with sponsor AT&T Media Services, will host a local Cable Positive observation of the 12th annual World AIDS Day on Wednesday, Dec. 1 from noon to 8 p.m. Metreon, which draws families and young people, was chosen to complement the youth-targeted theme of
EAST LOS ANGELES--(BUSINESS WIRE)--Nov. 18, 1999--The Wall/Las Memorias Project will present the sixth annual Noche de Memorias (Night of Memories) on World AIDS Day, Wednesday, Dec. 1, 1999, to honor and celebrate the lives of friends and family who have died of AIDS. The evening s schedule of activities will take pla
ALAMEDA, Calif.--(BUSINESS WIRE)--November 18, 1999-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the U.S. Food and Drug Administration ( FDA ) approved a Day Assay license supplement to its Cambridge Biotech Human Immunodeficiency Virus Type 1 (HIV-1) Western Blot test that confirms the presence
LAS VEGAS--(BW Healthwire)--Nov. 17, 1999--Steroidogenesis (OTCBB:STGI) says a recent article (November 12, 1999) by Haase et al, published in the prestigious SCIENCE in London, brings out pertinent news about the limitations of the current AIDS therapy. This article documents that the present anti-viral therapy (retro
MCLEAN, Va.--(BW HealthWire)--Nov. 17, 1999--Shalom Z. Hirschman, M.D., President and CEO of Advanced Viral Research Corp. (OTCBB:ADVR), reported yesterday that the experimental drug, Substance R (Reticulose(TM)), appears to turn on the body s beneficial response to fight viral infections, including HIV (human immunode
SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Nov. 15, 1999-- ChromaVision Medical Systems Inc. (Nasdaq:CVSN), developer of unique cellular imaging diagnostics and manufacturer of the Automated Cellular Imaging System (ACIS)(TM), Monday announced a collaboration with the University of California, Los Angeles, School of
SAN FRANCISCO--(BUSINESS WIRE)--Nov. 15, 1999--Whether bidding from a Yahoo!-wrapped taxi while driving the streets of San Francisco or participating from home, people now can support the San Francisco AIDS Foundation (SFAF) wherever they are. Beginning today and running through Nov. 22, Yahoo!(R) (Nasdaq:YHOO) Auction
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 25, 1999-- ShamanBotanicals.com announces the presentation of positive results from clinical trials involving SB-Normal Stool Formula(TM), a proprietary new botanical dietary supplement, at the European AIDS Conference in Lisbon,
Trimeris, Inc. (Nasdaq: TRMS) and Hoffmann-La Roche Inc. announced today new 16-week results from an evaluation of T-20 in an on-going Phase II clinical trial (T-20-205). T-20 is a peptide that inhibits HIV, the virus known to cause AIDS, and is the first member of a new class of investigational antiretroviral compound
TORONTO--(BUSINESS WIRE)--Sept. 24, 1999--HIV-VAC, Inc (OTC BB:HIVC), developer of a promising new vaccine for AIDS, announced its concern for HIV infected patients as regards the findings of a recent study by the Aaron Diamond AIDS Research Center at Rockefeller University in New York. The study of 80 men found that t
ATLANTA--(BUSINESS WIRE)--Sept. 21, 1999--While dramatic acts of violence have turned an intense spotlight on today s youth culture, a significant risk to the well being of young people is being overlooked by many parents and educators around the world. Results of the 1999 Durex Global Sex Survey released today show th
Seattle s CHICKEN SOUP BRIGADE will receive a $40,000 grant from Philip Morris Companies Inc. to expand its emergency food program and support services for people living with AIDS/HIV. Check Presentation Ceremony Monday, September 13, 1999 10:00 a.m. Chicken Soup Brigade Main Building 1002 East Seneca (10th Avenue
BEAVERTON, Ore.--(BW HealthWire)--Sept. 13, 1999--Epitope, Inc. (NASDAQ NM: EPTO) today announced that supplies of the Company s OraSure(R) oral specimen collection device will be donated for use during the Harlem Health Expo, a free education program taking place in New York City on September 15. The day-long Expo is
ALAMEDA, Calif.--(BUSINESS WIRE)--Sept. 2, 1999--Findings regarding the significance of detecting HIV-1 antibodies in the urine of individuals who test negative to HIV-1 in blood tests were reported by scientists from Calypte Biomedical Corporation (NASDAQ: CALY) in the September 1 issue of the peer-reviewed journal Cl
TORONTO--(BUSINESS WIRE)--Aug. 24, 1999--HIV-VAC, Inc., (OTC BB:HIVC) has announced that the Company has received a funding commitment totaling $5 million from an Australian investment group to complete initial test trials of HIV-VAC s AIDS vaccine with the Russian Aids Centre, and later proceed to the Phase III trials
ISELIN, N.J.--(BUSINESS WIRE)--Aug. 23, 1999--Bio-Technology General Corp. (NASDAQ: BTGC) announced today that it has received a notice of allowance from the United States Patent and Trademark Office for a patent application with claims to the use of oxandrolone in the treatment of HIV Wasting Syndrome. This follows th
BRAINTREE, Mass.--(BW HealthWire)--Aug. 17, 1999--Today, the Food and Drug Administration as well as Health Canada issued guidance to each nation s blood collection agencies which prohibits them from collecting blood from anyone who has visited the United Kingdom for an extended period of time since 1980.
(BUSINESS WIRE FEATURES)--August 17, 1999--Just a few years ago, American condom manufacturers were trying to sell condoms like parachutes: You wouldn t jump out of a plane without one, would you? -- Trojan print ad, circa 1996 Only recently have condom manufacturers begun to realize a key fact that had been previously
TORONTO--(BUSINESS WIRE)--Aug. 12, 1999--HIV-VAC, Inc, (OTC BB:HIVC) is being featured on one of the Internet s leading investor relations sites: http://www.stockhouse.com/snapshots/hivc/, which has over 15 million visitors each month. HIV-VAC s HIV vaccine was originally developed by Dr. Gordon Skinner, MD (Hons), DSc
MALIBU, Calif.-- (BUSINESS WIRE)--Aug. 12, 1999--More than 1,500 athletes, celebrities, musicians and weekend warriors will hit the beach in Malibu on Sunday, Sept. 19, to participate in the 13th Annual Nautica Malibu Triathlon. The race will begin at 7:15 a.m. Competitors will challenge themselves as well as each othe
LAKEWOOD, N.J.--(BUSINESS WIRE)--Aug., 11, 1999--Joseph Sanpietro, President of Medi-Hut Co., Inc. (OTC BB: MHUT), announced today that needle safety legislation has passed in the States of California, Tennessee, Maryland and New Jersey mandating the use of needle-safety devices in the Health Care Facilities with anoth
LOS ANGELES--(BUSINESS WIRE)--July 28, 1999-- $98,500 in Awards from Philip Morris Companies Inc. Responds to the Changing Face of the AIDS Epidemic Today, seven AIDS service organizations across California serving people living with HIV/AIDS received Positive Helpings awards totaling $98,500 from Philip Morris Compani
LAS VEGAS--(BW HealthWire)--July 28, 1999--Dr. Alfred T. Sapse, President of Steroidogenesis Inhibitors International (OTC BB:STGI), announced today that the AIDS ReSearch Alliance has completed the screening and assessment process, and enrollment for the first cohort of patients has commenced with Anticort s pharmacok
MARINA DEL REY, Calif.--(BUSINESS WIRE)--July 22, 1999--To Help Celebrate Project Angel Food s 10th Anniversary, New Site is Launched at the Organization s 1999 Angel Awards To help Los Angeles-based non-profit organization Project Angel Food celebrate its 10th anniversary, Bush Communications Inc., a Marina Del Rey ma
LAS VEGAS--(BW HealthWire)--July 21, 1999--New Technologies & Concepts, Inc. (NTC), regarding its press release of July 19, 1999, wishes to clarify certain points made in the press release. First, we would like to clarify the portion of the press release referring to documentation from the Government of
HUNTSVILLE, Ala.--(BW HealthWire)--July 19, 1999-- Experts provide up-to-date information about HIV diagnosis and treatment--and answers for those supporting loved ones infected with the virus LiveOnTheNet, the AIDS Action Coalition of North Alabama and the Davis Clinic bring Web users the latest up-to-date information
LAS VEGAS--(BW HealthWire)--July 19, 1999--New Technologies & Concepts, Inc. (NTC), a Research and Development Company, announced today that as a follow-up to its announcement on June 16, 1999 of its major breakthrough in the fight against the human immunodeficiency virus (HIV), it has received documentation from t
ATLANTA--(BW HealthWire)--July 19, 1999--Atlanta-based AIDSMD(R), Inc. is announcing development of advanced technology that will provide patients and physicians access to state-of-the-art management of HIV disease and AIDS. AIDSMD(R) has developed the design for unique software that will interface with their website,
SCOTTSDALE, Ariz.--(BW HealthWire)--July 13, 1999--While most AIDS treatment specialists advocate intensive triple drug therapy for HIV/AIDS patients, actual prescribing by physicians and compliance by patients varies widely. This disparity was discovered in a study recently conducted by researchers at PCS Health Syste
DURHAM, N.C. and NUTLEY, N.J.--(BW HealthWire)--July 12, 1999-- Trimeris Inc. (NASDAQ: TRMS) and Roche have concluded an agreement for the full-scale clinical testing and development of Trimeris two novel anti-HIV fusion inhibitors, T-20 and T-1249. Roche will market the compounds worldwide. In the United
BALTIMORE--(BUSINESS WIRE)--July 7, 1999--A Thailand-based study of heterosexual transmission of the human immunodeficiency virus (HIV) has shown that both the infected male s CD4 lymphocyte count as well as the couple s history of sexually transmitted disease affect whether the female partner becomes infected with HIV
TORONTO--(BUSINESS WIRE)--July 7, 1999--HIV-VAC, Inc, (OTC BB:HIVC) announces the launch of a new corporate Internet Web Site which features in-depth information, including relevant scientific data, on the Company s AIDS vaccine at www.hivvac.com HIV-VAC s HIV vaccine was developed by Dr. Gordon Skinner, MD (Hons), DSc
VERNON, Conn.--(BW HealthWire)--July 6, 1999--California healthcare workers began breathing easier last week as the nation s first law mandating the use of safety needles went into effect on July 1st. The law requires that healthcare institutions provide workers with needles designed with engineered controls to aid in
(BUSINESS WIRE FEATURES)--Priced at $99.00, a 6 bedroom luxury Victorian Cape Cod set in the rolling foothills of the Allegheny Mountains southwest of Washington, D.C. will be signed over to the lucky winner of an international contest sponsored by the home s current owner. A substantial portion of the proceeds will be
ATLANTA--(BUSINESS WIRE)--July 6, 1999--Although the phrase let me slip into something more comfortable may not be used any more, a new study released today reveals comfort is still key. Durex Consumer Products, marketers of Durex, the world s leading condom brand, conducted a national online survey among 1,064 individ
`OKLAHOMA CITY--(BW HealthWire)--July 1, 1999--ZymeTx, Inc. (NASDAQ: ZMTX - news), a viral disease management company, announced it will return its license of the anti-HIV compound internally designated ZX-0851 to the Oklahoma Medical Research Foundation (OMRF). It was determined that the development of ZX-0851 will re
DURHAM, N.C.--(BW HealthWire)--July 1, 1999--Trimeris, Inc. (NASDAQ: TRMS) announced today that patient selection and dosing have begun in its T1249-101 Phase I clinical trial for T1249, the second of a new class of anti-HIV drugs that block the entry of the virus into cells. This dose escalation trial is designed to a
FOSTER CITY, Calif.--(BW HealthWire)--June 29, 1999-- Gilead Sciences , Inc. (Nasdaq: GILD) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for adefovir dipivoxil 60 mg, an investigational, once-daily, oral nucleotide reverse transcriptase inhibitor (RTI)
OLYMPIA, Wash.--(BUSINESS WIRE)--June 23, 1999--The State Board of Health will hold a public hearing July 14 at the Doubletree Inn, 18740 International Boulevard, SeaTac. A new rule on HIV reporting is the primary agenda item. The rule the board is considering for adoption is the result of more than a year s work, sai
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--June 23, 1999-- ViroLogic, Inc., a biotechnology company developing novel therapy guidance technology for viral diseases and cancer, today announced the commercial availability of PhenoSense(TM) HIV, the company s rapid phenotypic HIV drug resistance assay. In a time of ris
DURHAM, N.C.--(BW HealthWire)--June 23, 1999--Trimeris, Inc. (NASDAQ:TRMS) announced today that patient selection and dosing have begun in its T20-206 Phase II clinical trial for T-20. The trial will assess the antiviral activity and long-term safety of T-20 when used in combination with other anti-HIV drugs. T20-206 w
BALTIMORE--(BW HealthWire)--June 22, 1999-- Researchers have shown that when it comes to reducing the stigma of AIDS and explaining how the human immunodeficiency virus (HIV) is transmitted, live theater may be more effective than either the mass media or interpersonal counseling. The study evaluated audience knowledge
LAS VEGAS--(BW HealthWire)--June 16, 1999--New Technologies & Concepts, Inc. (NTC), a Research and Development Company, announced today that it has taken a major step in the fight against the human immunodeficiency virus (HIV). The founder of the company, Alfred Flores, an honor graduate of the University of Madrid
TORONTO--(BUSINESS WIRE)--June 16, 1999--HIV-VAC, Inc, (OTC BB:HIVC) has announced that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, the developer of HIV-VAC s AIDS vaccine, has reached an agreement with the Russia Aids Centre, who will conduct Phase I and Phase II trials of HIV-VAC s vaccine. They will late
SAN JOSE, Calif.--(BUSINESS WIRE)--June 9, 1999--AIDS Resources, Information & Services (ARIS), a non-profit organization, will honor former San Jose Mayor Susan Hammer for her contribution to AIDS prevention and support services for Santa Clara County at a formal dinner and silent auction on Friday, June 11. Mayor
VANCOUVER, Wash.--(BUSINESS WIRE)--June 9, 1999--Saliva Diagnostic Systems Inc. (OTC BB:SALV - news) announced today that in collaboration with its marketing partner in India , Cadila Healthcare Ltd., approval has been obtained from the Drug Controller of India (DCI) for distribution of its rapid, whole-blood test for
LOS ANGELES--(BUSINESS WIRE)--June 8, 1999--The Los Angeles County Office of AIDS Programs and Policy is promoting National HIV Testing Week from June 21-27 throughout Los Angeles County. During this week, more than 68 county-sponsored clinics will offer testing and prevention counseling for extended hours. The goal is
BERKELEY, Calif.--(BUSINESS WIRE FEATURES)--June 7, 1999--Why are people at Clif Bar Inc. bicycling a total of nearly 20,000 miles - almost the equivalent of a trip around the world - to help fight AIDS? From the CEO s office to the shipping dock, the people at Clif Bar have plunged wholeheartedly into the Tanqueray s
MIAMI--(BW HealthWire)--June 3, 1999-Americare Health Scan Inc. (OTC BB:AMIT) has issued a statement clarifying the status of its non-invasive HIV test, the Ana-Sal(R) saliva test kit. The company has not yet applied for approval from the U.S. Food and Drug Administration to distribute the test in the Unit
TORONTO, Ontario--(BUSINESS WIRE)--June 3, 1999--HIV-VAC, Inc, (OTC BB:HIVC) announced today that Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath, the developer of HIV-VAC s HIV vaccine has expressed interest in Immune Response Corp s (NASDAQ:IMNR) Remune HIV vaccine tests that have ended due to their minimal effect
PLANTATION, Fla.--(BW HealthWire)--May 26, 1999--Immunity Care and Research, LLC announced today it has begun a Phase I clinical trial with its investigational drug candidate, AG1549 a second generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection being developed by
VERNON, Conn.--(BW HealthWire)--May 20, 1999--The momentum toward mandating safe needles to protect health care workers continues to grow. Today in Washington, D.C., Representative Pete Stark (D-California) and Representative Marge Roukema (R-NJ) introduced a bill in Congress mandating the use safe needles for healthca
MIAMI--(BUSINESS WIRE)--May 18, 1999--Three more countries have approved the use of a new non-invasive HIV test, developed by Americare Health Scan, Inc. (OTC BB:AMIT). The company announced today that its new Ana-Sal(TM) saliva test kit has now been approved for use in Brazil , Arge
BRISBANE, Calif.--(BW HealthWire)--May 18, 1999--In honor of the Second Annual AIDS Vaccine Day, VaxGen , Inc. would like to thank the volunteers in our Phase III clinical trials of AIDSVAX(TM). Their invaluable contribution to HIV vaccine research is helping bring us closer to our goal: developing a safe and effective
DURHAM, N.C.--(BW HealthWire)--May 13, 1999--Trimeris, Inc. (NASDAQ: TRMS - news) announced today that T-1249 has received fast track designation from the United States Food and Drug Administration for the treatment of HIV infected individuals. T-1249 is the company s second drug candidate in a new class of anti-HIV co
NEW YORK--(BW HealthWire)--May 11, 1999-- Medscape (http://www.medscape.com), a leading provider of high-quality medical information on the Internet, today announced a powerful new enhancement to its HIV/AIDS interactive program that instantly generates a daily dosing schedule for multidrug HIV treatment regimens. Avai
TORONTO--(BUSINESS WIRE)--May 11, 1999--HIV-VAC, Inc., (OTC BB:HIVC) announced that Dr. Gordon Skinner, developer of a promising new vaccine for AIDS was interviewed by Wall Street Interview. This presentation can be heard in its entirety beginning on Tuesday, May 11th on the Internet at Wall Street Interview s web sit
FOSTER CITY, Calif.--(BW HealthWriters)--May 6, 1999-- Gilead Sciences , Inc. (NASDAQ: GILD - news) announced today the extension of its U.S. expanded access program for the investigational anti-HIV drug PREVEON (adefovir dipivoxil) to Europe, Canada and Australia .
OLYMPIA, Wash.--(BUSINESS WIRE)--May 5, 1999--The state Board of Health will meet May 12 from 9 a.m. to 5 p.m. at the Comfort Inn & Suites, 19333 Pacific Highway South, in Seattle. At 9:10 a.m, the board will hear public testimony on a proposed rule that would require statewide minimum standards for training and te
OLYMPIA, Wash.--(BUSINESS WIRE)--April 27, 1999--Want to know what s in your drinking water? Your local water supplier will be letting you know just that very soon. Under a new federal consumer information regulation, water utilities must inform their customers about the quality of their water, as well as other vital p
(BUSINESS WIRE)--April 20, 1999--HIV infections among women are on the rise, accounting for 28-percent of all new cases. Yet, even with this increase in HIV infections among women, they still represent only 9 to 15-percent of participants in HIV/AIDS clinical trials. Now, a new investigational study is underway at 20 i
SAN JOSE, Calif.--(BUSINESS WIRE)--April 23, 1999--Presenting at the Oak Ridge Conference of the American Association for Clinical Chemistry (AACC), Dr. Howard Urnovitz, chief scientific officer of Calypte Biomedical Corporation (NASDAQ: CALY), explained results of a significant clinical study of 826 individuals at hig
MONTVALE, N.J.--(BUSINESS WIRE)--April 23, 1999--In 1988, only 25% of nurses said they would never refuse to care for an AIDS patient. Today, that picture is reversed: More than 80% of nurses say they would never refuse care, according to a survey by RN(R) Magazine. Knowing how to protect themselves seems to be the key
DURHAM, N.C.--(BW HealthWire)--April 15, 1999-- Trimeris, Inc. (NASDAQ:TRMS - news) announced today that it filed with the FDA an Investigational New Drug application (IND) for T-1249, its second therapeutic in a new class of anti-HIV drugs that block the entry of the virus into cells. The FDA s 30-day review perio
COLLINGWOOD, ONTARIO, Canada--(BUSINESS WIRE)--April 14, 1999-- HIV-VAC, Inc. (OTC/BB: HIVC - news) has announced that they have acquired the worldwide rights to an HIV vaccine through an assignment of license agreement with Intracell Vaccines Limited. This technology is owned by the University of Birmingham, UK, under
EDMONTON, Alberta--(BUSINESS WIRE)--April 8, 1999--Warren Jackson, President and Chief Executive Officer of Altachem Pharma Ltd. (AAF) (ASE:AAF - news) is pleased to announce the receipt of the no objection letter from the Therapeutic Products Programme of Health Canada in Ottawa, Ontario for the proposed phase one hum
OLYMPIA, Wash.--(BUSINESS WIRE)--March 31, 1999--Public health officials and AIDS advocates will tell state legislators Thursday stronger measures are needed to protect personal medical information related to AIDS and sexually transmitted diseases. I believe we are very close to agreement on an HIV reporting system tha
PHOENIX--(BW HealthWire)--March 26, 1999--Results of a recent study to determine the effects of a spermicidal gel on active HIV cells shows the formula, currently marketed under the brand name Preventx(R), suppresses the growth of the virus in a stable human T-cell line. The study was developed to determine whether the
BERKELEY, Calif.--(BUSINESS WIRE)--March 24, 1999--As the AIDS epidemic enters its third decade, practitioners in private practice and agency settings must be prepared to competently address those with and affected by HIV. The spread of the disease has increased the need for those working in the field to understand the
NEWTOWN, Pa.--(BW HealthWire)--March 23, 1999--Key facts about HIV and AIDS are available from Scott-Levin s quarterly HIV Therapy Audit, which projects data from general and family practitioners, internists, and infectious disease specialists who are actively treating HIV patients. While the U.S. Centers for Disease C
FOSTER CITY, Calif.--(BW HealthWire)--March 19, 1999-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today preliminary results from two studies designed to evaluate a 60 mg once daily dose of PREVEON(R) (adefovir dipivoxil) for the treatment of HIV-infected patients. Results indicate that treatment with 60 mg monothe
ST. PETERSBURG, Fla.--(BW HealthWire)--Mar 16--The battle over medical marijuana is heating up with a key Institute of Medicine (IOM) report due out of Washington D.C. tomorrow. The study was commissioned by Clinton s anti-drug chief, General Barry McCaffrey to review claims that smoking marijuana can be therapeutic in
FOSTER CITY, Calif.--(BW HealthWire)--March 11, 1999--The PE Biosystems Division of Perkin-Elmer (NYSE:PKN - news) has announced the availability of a complete, automated system for standardized, sequence-based genotyping of resistance mutations in HIV. The HIV Genotyping System is expected to be of immediate use in in
ALAMEDA, Calif.--(BUSINESS WIRE)--March 11, 1999--The Chinese National Center for AIDS Prevention and Control (NCAIDS) announced today that it has selected Calypte Biomedical s (NASDAQ: CALY - news) non-invasive urine HIV test for wide-scale use within the Chinese health-care system. The urine HIV test will also be the
LAS VEGAS--(BW HealthWire)--March 8, 1999--Aids Research Alliance and Steroidogenesis Inhibitors International (OTCBB:STGI) today jointly announced the start of an HIV treatment study with ANTICORT(TM), a drug developed by STGI. ANTICORT, an anticortisol, immunomodulator drug, will be evaluated in HIV positive patients
BRANCHBURG, N.J.--(BW HealthWire)--March 3, 1999-- Roche today received marketing approval from the U.S. Food and Drug Administration ( FDA ) for its AMPLICOR HIV-1 MONITOR UltraSensitive Method. This test is now the most sensitive means to measure levels of HIV circulating in an infected person s blood ( viral load ).
FOSTER CITY, Calif.--(BW HealthWire)--March 3, 1999-- Gilead Sciences , Inc. (Nasdaq:GILD - news) announced today results from preliminary analyses of two studies designed to evaluate a 60 mg once daily dose of PREVEONŽ (adefovir dipivoxil) for the treatment of HIV-infected patients. Results from recently unblinded stu
YONKERS, N.Y.--(BW HealthWire)--Feb. 25, 1999--Advanced Viral Research Corp. (OTC BB:ADVR) announced Thursday that its scientists have discovered that its lead antiviral drug, Reticulose, inhibited the production of a key cellular receptor for HIV. Using CD4 positive T-lymphocytes, the scientists found that Reticulose
IRVINE, Calif.--(BUSINESS WIRE)--Feb. 25, 1999--As researchers race to find a cure for HIV/AIDS, new drugs are being introduced that extend life for those who are HIV-infected. The largest and most comprehensive HIV/AIDS service provider in Orange County, the AIDS Services Foundation, reported that client deaths have d
BRISBANE, Calif.--(BW HealthWire)--Feb. 9, 1999-- VaxGen , Inc. today announced that Thailand s Ministry of Public Health (MOPH) has approved the start of a large-scale clinical trial of the company s AIDSVAX B/E preventive vaccine against the HIV strains that cause AIDS in Asia and the Pacific Rim. This marks the
DURHAM, N.C.--(BW HealthWire)--Feb. 4, 1999--Trimeris, Inc. (NASDAQ: TRMS) announced today that T-20, the first of a new class of anti-HIV drugs that block the entry of the virus into cells, has received fast track designation from the United States Food and Drug Administration for the treatment of HIV infected individ
LOS ANGELES--(BUSINESS WIRE FEATURES)--Feb. 2, 1999--Women often have difficulty purchasing men s condoms, either from embarrassment or confusion. Condoms have always been marketed to men by men. Traditionally men have been entrusted with buying condoms and with using them, but they don t seem to be doing all that good
BOSTON--(BW HealthWire)--Feb. 1, 1999--In a study that confirms warnings issued by researchers four years ago, the same researchers now report that both infant and adult monkeys vaccinated with a live, weakened form of an HIV-like virus have developed AIDS from the vaccine virus itself. Because the virus used in the st
MORRIS PLAINS, N.J.--(BUSINESS WIRE)--Jan. 26, 1999-- Warner-Lambert Company (NYSE:WLA - news) today announced a definitive agreement to acquire Agouron Pharmaceuticals, Inc. (Nasdaq:AGPH - news), an integrated pharmaceutical company committed to the discovery and development of innovative therapeutic products for trea
Trimeris, Inc. (NASDAQ: TRMS) announced today that preliminary results from TRI-003, a Phase II clinical trial of T-20, a fusion inhibitor, will be presented at the upcoming 6th Conference on Retroviruses and Opportunistic Infections in Chicago. T-20 attacks HIV in an entirely different way than currently approved agen
STANFORD, Calif.--(BW HealthWire)--Jan. 20, 1999--Protease inhibitors, the drugs now routinely used to treat HIV in the United States , are highly effective against the viral strain thought to be most prevalent worldwide, Stanford researchers report in a new study. HIV drugs developed in this country are only tested ag
KEYSTONE, Colo.--(BW HealthWire)--Jan. 14, 1999--Epimmune Inc., a majority-owned subsidiary of Cytel Corp. (Nasdaq:CYTL), today announced presentations by its scientists and collaborators of initial data suggesting that epitope-based vaccines hold promise for the control of HIV infection. Data from two HIV related mode
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Jan. 12, 1999-- Shaman Pharmaceuticals, Inc. (Nasdaq:SHMN) announced that it enrolled as planned at the end of December the first patients in an open-label study of SP-303/Provir(TM) for the treatment of diarrhea in people with AIDS to provide access to the drug for some pa
POMPANO BEACH, Fla.--(BUSINESS WIRE)--Jan. 6, 1999--In a civil lawsuit related to saliva collector technology for an HIV diagnostic test, a jury in Broward County (Florida) recently found that Technical Chemicals & Products, Inc. (Nasdaq:TCPI - news) did not misappropriate trade secrets. However, subject to final j
STANFORD, Calif.--(BW HealthWire)--Jan. 4, 1999--Hemophilia patients may benefit from a gene therapy technique that moderates or cures the bleeding disorder in mice and dogs, according to a study reported in the January issue of Nature Medicine. The researchers found that a single infusion of an engineered DNA delivery
This information is designed to support, not replace, the relationship that exists between you and your doctor.